Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Sep;23(9):2807-2813.
doi: 10.1111/jocd.16356. Epub 2024 May 12.

Safety and efficacy of tofacitinib in 97 alopecia areata patients

Maryam Nasimi  1 , Robabeh Abedini  1 , Narges Ghandi  1 , Amir Teymourpour  2 , Hanie Babaie  3
Affiliations
Review

Safety and efficacy of tofacitinib in 97 alopecia areata patients

Maryam Nasimi et al. J Cosmet Dermatol. 2024 Sep.

Abstract

Background: Alopecia areata (AA) is a recurrent immune-mediated disorder causing hair loss without any scarring being present. It affects hairs on the head or other parts of the body and can occur at any age and in both genders. It seems that AA is associated with a higher rate of psychological disorders resulting from hair loss and the esthetic and social repercussions of it. Common treatments like corticosteroids do not work for every patient and recent treatment options focusing on the immunologic mechanisms like tofacitinib have shown some promising results.

Methods: It's a retrospective study on patients with AA, AT, AU taking oral tofacitinib as a treatment for at least 6 months. Scalp hair loss was assessed before treatment and at each visit using the Severity of Alopecia Tool (SALT) score.

Results: Of 97 cases, 69.1% demonstrated over 50% SALT score improvement, with 44.3% having 90% or more decrease in SALT score. Patients who suffered from patchy AA were more responsive compared to patients with AT and AU subtypes and had a greater percent change in SALT score. Tofacitinib was tolerated quite well and no significant adverse events were reported.

Conclusions: Tofacitinib should be taken into consideration as an efficacious treatment option for patients with AA, AT and AU.

Keywords: SALT score; alopecia areata; tofacitinib.

PubMed Disclaimer

References

REFERENCES

    1. Darwin E, Hirt PA, Fertig R, Doliner B, Delcanto G, Jimenez JJ. Alopecia areata: review of epidemiology, clinical features, pathogenesis, and new treatment options. Int J Trichology. 2018;10(2):51‐60.
    1. Szilveszter KP, Németh T, Mócsai A. Tyrosine kinases in autoimmune and inflammatory skin diseases. Front Immunol. 2019;10:1862.
    1. Padda IS, Bhatt R, Parmar M. Tofacitinib. StatPearls. StatPearls Publishing; 2023.
    1. Almutairi N, Nour TM, Hussain NH. Janus kinase inhibitors for the treatment of severe alopecia areata: an open‐label comparative study. Dermatology. 2019;235(2):130‐136.
    1. Olsen E, Hordinsky M, McDonald‐Hull S, et al. Alopecia areata investigational assessment guidelines. National Alopecia Areata Foundation. J Am Acad Dermatol. 1999;40:242‐246.

MeSH terms

LinkOut - more resources